CTNM

Contineum Therapeutics, Inc. CTNM

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-15.15M

Quarter to Jun 30

Free cash flow

$-11.51M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$500.56M total
SUVRETTA CAPITAL MANAGEMENT, LLC
$46.57M0.0%
Jupiter Topco LLC
$44.77M--
BlackRock, Inc.
$33.83M+208.5%
JOHNSON & JOHNSON
$32.44M0.0%
FRANKLIN RESOURCES INC
$30.14M0.0%
BALYASNY ASSET MANAGEMENT L.P.
$24.96M-9.7%
VANGUARD CAPITAL MANAGEMENT LLC
$21.66M+8.8%
PERCEPTIVE ADVISORS LLC
$20.58M0.0%
FMR LLC
$17.05M+27.6%
MILLENNIUM MANAGEMENT LLC
$15.27M-39.3%
GREAT POINT PARTNERS LLC
$15.10M+15.2%
Longaeva Partners L.P.
$13.32M+11.0%
Ikarian Capital, LLC
$13.24M0.0%
SECTORAL ASSET MANAGEMENT INC
$11.93M0.0%
GEODE CAPITAL MANAGEMENT, LLC
$11.36M+145.8%
Hillhouse Capital Advisors, Ltd.
$10.97M0.0%
Red Tree Management, LLC
$10.46M0.0%
Versant Venture Management, LLC
$8.89M0.0%
GOLDMAN SACHS GROUP INC
$8.15M+61.9%
Boxer Capital Management, LLC
$8.10M0.0%
STATE STREET CORP
$6.98M+320.5%
CITADEL ADVISORS LLC
$6.50M+13.2%
ADAGE CAPITAL PARTNERS GP, L.L.C.
$5.38MNew
SILVERARC CAPITAL MANAGEMENT, LLC
$4.85M-1.9%
ADAR1 Capital Management, LLC
$4.57M+0.8%
See all 102 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/CTNM

Earnings Per Share

13fpro.ai/company/CTNM

Loading ratio trend…

CTNM key financials by period

Reported revenue, net income and operating margin by fiscal year, from Contineum Therapeutics, Inc.'s annual filings on SEC EDGAR.

Contineum Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2023$50.0M$22.7M32.1%
Source: CTNM filings on SEC EDGAR →

CTNM insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Contineum Therapeutics, Inc. (CTNM): stock profile, AI score and financials

Contineum Therapeutics, Inc. (CTNM) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. CTNM is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Contineum Therapeutics, Inc. reports net income of $-15.2M, free cash flow of $-11.5M. Top institutional holders of CTNM by reported 13-F value include SUVRETTA CAPITAL MANAGEMENT, Jupiter Topco, BlackRock, based on the most recent SEC filings. CTNM trades on the Nasdaq exchange and files with the SEC under CIK 1855175. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CTNM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Contineum Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1855175 →